Triomics nabs $22M to bring oncology-specific AI to cancer centers

Triomics, a startup building an AI-powered platform to help oncologists and administrative staff automate tasks such as clinical trial matching and appointment preparation, has raised 22 million dollars in Series B funding. The round was led by Battery Ventures with participation from Nexus Venture Partners, Lightspeed, Y Combinator and others. The company was founded in 2021 and raised 15 million dollars in a Series A round in mid-2024. It initially focused on clinical trial matching before expanding its platform with verifiable patient summaries as part of a visit-preparation workflow. These summaries surface key information within the tools clinicians already use. Triomics automates the submission of tumor reports to government registries, a requirement for cancer centers. Co-founder Sarim Khan said the company has seen medical records with thousands of pages of information. Institutions including Memorial Sloan Kettering and Yale Cancer Center use Triomics because its models are trained on oncology data, Khan explained. The startup competes with AI medical scribes such as Abridge and Microsoft Nuance in summarizing patient charts. Khan said the company expanded its enterprise customer base fourfold over the past year, resulting in a tenfold increase in annualized recurring revenue.